Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SNDX Syndax Pharmaceuticals, Inc.

未开盘 02-24 16:00:00 EST

20.53

+0.63

+3.17%

盘后20.25

-0.28-1.36%

19:34 EST

最高20.64	最低19.78	成交量66.51万
今开19.97	昨收19.90	日振幅4.30%
总市值17.84亿	流通市值14.93亿	总股本8,691万
成交额1,358万	换手率0.91%	流通股本7,272万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals, Inc. ","latestPrice":20.53,"timestamp":1771966800000,"preClose":19.9,"halted":0,"volume":665078,"hourTrading":{"tag":"盘后","latestPrice":20.25,"preClose":20.53,"latestTime":"19:34 EST","volume":34191,"amount":701889.7295,"timestamp":1771979679130,"change":-0.28,"changeRate":-0.013639,"amplitude":0.013639},"delay":0,"changeRate":0.03165829145728656,"floatShares":72721425,"shares":86914838,"eps":-3.600392,"marketStatus":"未开盘","change":0.63,"latestTime":"02-24 16:00:00 EST","open":19.97,"high":20.635,"low":19.78,"amount":13580366.683301998,"amplitude":0.042965,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.600392,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772010000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1456981200000,"exchange":"NASDAQ","adjPreClose":19.9,"preHourTrading":{"tag":"盘前","latestPrice":19.8,"preClose":19.9,"latestTime":"08:43 EST","volume":34,"amount":677.5300699999999,"timestamp":1771940628220,"change":-0.1,"changeRate":-0.005025,"amplitude":0.015075},"postHourTrading":{"tag":"盘后","latestPrice":20.25,"preClose":20.53,"latestTime":"19:34 EST","volume":34191,"amount":701889.7295,"timestamp":1771979679130,"change":-0.28,"changeRate":-0.013639,"amplitude":0.013639},"volumeRatio":0.653948,"impliedVol":0.7755,"impliedVolPercentile":0.572},"requestUrl":"/m/hq/s/SNDX/wiki","defaultTab":"wiki","newsList":[{"id":"2608791874","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘大幅拉升5.47%报21.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608791874","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608791874?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:41","pubTimestamp":1770043307,"startTime":"0","endTime":"0","summary":"北京时间2026年02月02日22时41分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.47%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.16%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202224147a473c3c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202224147a473c3c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"1152010127","title":"Syndax Pharmaceuticals在摩根大通第44届医疗健康年会公布2025年初步财务数据及业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1152010127","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152010127?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:04","pubTimestamp":1768219473,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals于摩根大通第44届年度医疗健康会议上，披露了2025年初步财务业绩要点，并同步更新了公司最新业务动态。此次发布凸显了公司在财务运营与战略推进方面的关键进展，为投资者提供了前瞻性视角。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"1147776210","title":"Syndax Pharmaceuticals全球布局：新药项目将登陆欧亚大陆、中欧、东南欧、以色列、中东及土耳其、拉美和非洲地区","url":"https://stock-news.laohu8.com/highlight/detail?id=1147776210","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147776210?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:06","pubTimestamp":1767787611,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals, Inc.宣布，其创新药物项目将在欧亚大陆部分区域、中欧与东南欧、以色列、中东及土耳其、拉丁美洲以及非洲多地同步启动。这一战略性部署标志着公司全球化进程迈出关键一步，旨在为更广泛的患者群体提供前沿治疗方案。\n项目落地范围横跨多个大洲，覆盖新兴市场与成熟医疗体系区域。通过整合各地临床资源与监管优势，Syndax将加速推进药物在全球范围内的可及性，为不同地域的医疗需求提供差异化解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2589272354","title":"Syndax公布AML联合疗法强劲数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2589272354","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589272354?lang=zh_cn&edition=full","pubTime":"2025-12-08 23:42","pubTimestamp":1765208520,"startTime":"0","endTime":"0","summary":"美股周一早盘，临床阶段的生物制药公司Syndax（SNDX）股价下跌3.2%。该公司在2025年美国血液学会（ASH）年会上展示了revumenib联合疗法的最新数据，在新诊断和移植后急性髓系白血病患者队列中显示出高缓解率和高微小残留病阴性率。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-08/doc-inhachkx2122015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4109","BK4139","ASH","LU2463526074.USD","SNDX"],"gpt_icon":0},{"id":"2585198332","title":"Syndax Pharmaceuticals, Inc.盘中异动 大幅拉升5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585198332","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585198332?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:50","pubTimestamp":1763650225,"startTime":"0","endTime":"0","summary":"北京时间2025年11月20日22时50分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.15%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.51%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511202250259775c9ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511202250259775c9ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2579926172","title":"Syndax Pharmaceuticals, Inc.盘中异动 快速拉升5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579926172","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579926172?lang=zh_cn&edition=full","pubTime":"2025-10-29 00:48","pubTimestamp":1761670128,"startTime":"0","endTime":"0","summary":"北京时间2025年10月29日00时48分，Syndax Pharmaceuticals, Inc.股票出现异动，股价大幅拉升5.03%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029004848974708f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029004848974708f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"1143402682","title":"FDA 批准 Revumenib 治疗带有易感 Npm1 突变的复发或难治性急性髓性白血病","url":"https://stock-news.laohu8.com/highlight/detail?id=1143402682","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143402682?lang=zh_cn&edition=full","pubTime":"2025-10-25 01:15","pubTimestamp":1761326113,"startTime":"0","endTime":"0","summary":"FDA 批准 Revumenib 治疗带有易感 Npm1 突变的复发或难治性急性髓性白血病","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"1172232207","title":"Syndax Pharmaceuticals 股价在盘前上涨2.4%，因H.C. Wainwright 開始给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1172232207","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172232207?lang=zh_cn&edition=full","pubTime":"2025-10-16 18:15","pubTimestamp":1760609710,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals 股价在盘前上涨2.4%，因H.C. Wainwright 开始给予买入评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2565051642","title":"Syndax Pharmaceuticals, Inc.盘中异动 临近午盘急速上涨5.00%报17.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2565051642","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565051642?lang=zh_cn&edition=full","pubTime":"2025-09-05 23:40","pubTimestamp":1757086819,"startTime":"0","endTime":"0","summary":"北京时间2025年09月05日23时40分，Syndax Pharmaceuticals, Inc.股票出现异动，股价快速上涨5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.02%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。消息层面，截至23时40分，《高盛集团维持Syndax Pharmaceuticals买入评级，上调目标价至24美元》资讯为影响Syndax Pharmaceuticals, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905234020a4b69f70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905234020a4b69f70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","DX","BK4139","BK4110"],"gpt_icon":0},{"id":"2518278453","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278453","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518278453?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:22","pubTimestamp":1741616534,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时22分，Syndax Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.07%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.47%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3400.89%、719.71%、414.19%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Biodexa Pharmaceuticals Plc，振幅分别为41.36%、40.24%、39.34%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222215a26a3846&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222215a26a3846&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2518447940","title":"Syndax Pharmaceuticals, Inc.2024财年实现净利润-3.19亿美元，同比减少52.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518447940","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518447940?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449670,"startTime":"0","endTime":"0","summary":"3月9日，Syndax Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-3.19亿美元，同比减少52.63%；其中营业收入为23.68百万美元，每股基本收益为-3.72美元。机构评级：截至2025年3月9日，当前有14家机构对Syndax Pharmaceuticals, Inc.目标价做出预测，其中目标均价为36.29美元，其中最低目标价为16.00美元，最高目标价为51.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000232a266b3dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000232a266b3dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2517660179","title":"花旗：维持Syndax Pharmaceuticals(SNDX.US)评级，由买入调整至买入评级, 目标价由45.00美元调整至42.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517660179","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517660179?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:02","pubTimestamp":1741107763,"startTime":"0","endTime":"0","summary":"花旗：维持Syndax Pharmaceuticals(SNDX.US)评级，由买入调整至买入评级, 目标价由45.00美元调整至42.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05010248524002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SNDX"],"gpt_icon":0},{"id":"2516772356","title":"Syndax Pharmaceuticals, Inc.盘中异动 急速下挫6.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516772356","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516772356?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:33","pubTimestamp":1741098834,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时33分，Syndax Pharmaceuticals, Inc.股票出现异动，股价快速下跌6.10%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Exicure, Inc.涨幅较大，Windtree Therapeutics, Inc.、Aeon Biopharma, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1060.12%、1057.97%、418.64%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Adma Biologics Inc、Ibio, Inc.，振幅分别为23.30%、12.57%、11.23%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223354abe7f059&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223354abe7f059&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2516637631","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.50%报16.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637631","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516637631?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:31","pubTimestamp":1741012300,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时31分，Syndax Pharmaceuticals, Inc.股票出现异动，股价大幅拉升5.50%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.20%、24.44%、22.45%，振幅较大的相关个股有Entero Therapeutics Inc.、Cibus, Inc.、Galmed Pharmaceuticals Ltd.，振幅分别为15.16%、9.55%、9.35%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223140989a0f5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223140989a0f5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2516803756","title":"Syndax Pharmaceuticals(SNDX.US)：2024年Q4财报实现营收768万美元，前值为0美元，预期值为2223万美元；每股收益为-1.10美元，前值为-1.00美元，预期值为-1.08美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516803756","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516803756?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:13","pubTimestamp":1741003986,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals(SNDX.US)：2024年Q4财报实现营收768万美元，前值为0美元，预期值为2223万美元；每股收益为-1.10美元，前值为-1.00美元，预期值为-1.08美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03201348492140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SNDX"],"gpt_icon":0},{"id":"1115785598","title":"Syndax Pharmaceuticals 2024年第四季度GAAP每股收益$(1.10)低于预期$(1.01)，销售额$7.68M低于预期$85.91M","url":"https://stock-news.laohu8.com/highlight/detail?id=1115785598","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115785598?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:10","pubTimestamp":1741003813,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals  公布其季度每股亏损为$，低于分析师普遍预期的$，差距为8.91%。这是比去年同期每股亏损$减少了10%。以上内容来自Benzinga Earnings专栏，原文如下：Syndax Pharmaceuticals  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 8.91 percent. This is a 10 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $7.68 million which missed the analyst consensus estimate of $85.91 million by 91.06 percent.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Syndax Pharmaceuticals 2024年第四季度GAAP每股收益$(1.10)低于预期$(1.01)，销售额$7.68M低于预期$85.91M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2514185187","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘大幅上涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514185187","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514185187?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:55","pubTimestamp":1740581709,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时55分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速上涨5.05%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.31%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Humacyte Inc C/Wts 27/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为4317.10%、151.99%、132.86%，振幅较大的相关个股有Enveric Biosciences, Inc.、Humacyte Inc C/Wts 27/08/2026 、Renovaro Inc.，振幅分别为127.12%、39.47%、29.31%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226225509abddf2dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226225509abddf2dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2514869775","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514869775","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514869775?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:46","pubTimestamp":1740411998,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时46分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速下跌5.01%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Addex Therapeutics Limited涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为228.64%、96.48%、28.21%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为151.09%、55.69%、53.34%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224234639abdb1f9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224234639abdb1f9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2513299714","title":"Syndax Pharmaceuticals, Inc.盘中异动 大幅拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513299714","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513299714?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:45","pubTimestamp":1740149114,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时45分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.42%。其相关个股中，Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Omega Therapeutics, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为80.32%、78.89%、35.14%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Omega Therapeutics, Inc.，振幅分别为50.31%、46.92%、35.45%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221224514abd7b29f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221224514abd7b29f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2509427249","title":"Syndax Pharmaceuticals, Inc.股价上涨10.17% 市值涨1.4亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509427249","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509427249?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:31","pubTimestamp":1738852272,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时31分，Syndax Pharmaceuticals, Inc.股票出现异动，股价大幅上涨10.17%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Lipella Pharmaceuticals Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Transcode Therapeutics, Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为3685.57%、328.87%、113.29%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Moleculin Biotech, Inc.、Invivyd, Inc.，振幅分别为19.38%、10.08%、9.48%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223112abc4d41e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223112abc4d41e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0138},{"period":"3month","weight":0.0332},{"period":"6month","weight":0.258},{"period":"1year","weight":0.3101},{"period":"ytd","weight":-0.0228}],"compareEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0113},{"period":"6month","weight":0.0592},{"period":"1year","weight":0.1509},{"period":"ytd","weight":0.008}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Syndax Pharmaceuticals, Inc.于2005年10月11日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，正在开发癌症疗法的创新管道。该公司正在开发revumenib，这是一种有效的、选择性的、menin-MLL结合相互作用的小分子抑制剂，用于治疗KMT2A重排或KMT2AR，也称为混合谱系白血病重排或MLLR，包括急性淋巴细胞白血病或ALL在内的急性白血病，以及急性髓细胞白血病或AML，以及necleophosmin 1，也称为NPM1，突变AML。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.039298},{"month":2,"riseRate":0.7,"avgChangeRate":0.074569},{"month":3,"riseRate":0.555556,"avgChangeRate":0.051247},{"month":4,"riseRate":0.4,"avgChangeRate":0.014629},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019495},{"month":6,"riseRate":0.5,"avgChangeRate":-0.003538},{"month":7,"riseRate":0.6,"avgChangeRate":0.016261},{"month":8,"riseRate":0.6,"avgChangeRate":0.106119},{"month":9,"riseRate":0.5,"avgChangeRate":-0.031411},{"month":10,"riseRate":0.2,"avgChangeRate":-0.077781},{"month":11,"riseRate":0.6,"avgChangeRate":0.04592},{"month":12,"riseRate":0.5,"avgChangeRate":0.035938}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals, Inc. ","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Syndax Pharmaceuticals, Inc. ,SNDX,Syndax Pharmaceuticals, Inc. 股票,Syndax Pharmaceuticals, Inc. 股票老虎,Syndax Pharmaceuticals, Inc. 股票老虎国际,Syndax Pharmaceuticals, Inc. 行情,Syndax Pharmaceuticals, Inc. 股票行情,Syndax Pharmaceuticals, Inc. 股价,Syndax Pharmaceuticals, Inc. 股市,Syndax Pharmaceuticals, Inc. 股票价格,Syndax Pharmaceuticals, Inc. 股票交易,Syndax Pharmaceuticals, Inc. 股票购买,Syndax Pharmaceuticals, Inc. 股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}